Funded Health Care Startups in Mountain View
The disclosed check sizes in Mountain View cluster into a mid-range, but one entry breaks away: Mindstrong’s $100M round dated 2020-05-21 is the only discl…
The disclosed check sizes in Mountain View cluster into a mid-range, but one entry breaks away: Mindstrong’s $100M round dated 2020-05-21 is the only disclosed amount above $50M, while the next-largest disclosed amount is Materna Medical’s $20M (2024-05-21). The smaller rounds stack much closer together, including Selera Medical’s $500K (2024-04-03) near the bottom of the disclosed range and several single-digit million rounds such as Smartlens ($5M, 2025-10-16), Digbi Health ($5M, 2021-03-18), and Underdog Pharmaceuticals ($10M, 2021-09-23).
Temporally, the 11 most recent rows span 2020-05-21 through 2025-11-12, with multiple 2023 rounds (Aumet on 2023-03-16 at $7M; Acesis on 2023-11-16 at $3M; Revelle Aesthetics on 2023-06-01 at $30M) and a 2024 wave centered on April–May (Selera Medical $500K on 2024-04-03; Materna Medical $20M on 2024-05-21). Stage labeling is mixed: 3 of the 11 rows are “Series Unknown” (Smartlens 2025-10-16, Acesis 2023-11-16, Revelle Aesthetics 2023-06-01), and 1 row is explicitly “undisclosed” (AliveCor on 2022-08-16).
Most recent rounds
11 shownRelated listings
Frequently asked
Which disclosed round is the outlier in this Mountain View health care set, and how does it compare to the rest?
Mindstrong’s $100M round (2020-05-21) is the only disclosed amount above $50M; it dwarfs the next-largest disclosed entry, Materna Medical’s $20M on 2024-05-21. The rest of the disclosed rounds sit well below $20M, including Selera Medical’s $500K on 2024-04-03.
Do the rounds cluster in time, especially around 2023–2024 versus other years?
There is a noticeable 2024 concentration: Selera Medical closes on 2024-04-03 at $500K and Materna Medical follows on 2024-05-21 at $20M. 2023 also groups multiple entries, including Aumet on 2023-03-16 ($7M) and Revelle Aesthetics on 2023-06-01 ($30M), before Acesis on 2023-11-16 ($3M).
How many entries have non-specific or missing disclosed amounts, and does that affect comparisons?
One row is explicitly undisclosed (AliveCor, 2022-08-16), so disclosed-amount comparisons exclude it. Separately, 3 of 11 rows carry “Series Unknown” labels (Smartlens 2025-10-16 $5M; Acesis 2023-11-16 $3M; Revelle Aesthetics 2023-06-01 $30M), which limits stage-based ordering even when amounts are disclosed.
What stage mix dominates the segment when looking only at the listed rounds?
No single stage dominates: the list includes Series A (NextSense 2025-11-12 $16M; Digbi Health 2021-03-18 $5M), with other stages spread across Series B (Materna Medical 2024-05-21 $20M), Seed (Aumet 2023-03-16 $7M; Underdog Pharmaceuticals 2021-09-23 $10M; plus AliveCor is undisclosed), and Pre-Seed (Selera Medical 2024-04-03 $500K).
How recent is the set, and which entry anchors the newest and oldest ends?
The rows span from 2020-05-21 (Mindstrong, $100M) to 2025-11-12 (NextSense, $16M). Several of the most recent entries are concentrated in 2025, including NextSense on 2025-11-12 ($16M) and Smartlens on 2025-10-16 ($5M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.